ERΑ+ BREAST CANCER
Clinical trials for ERΑ+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ERΑ+ BREAST CANCER trials appear
Sign up with your email to follow new studies for ERΑ+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to slow advanced breast cancer
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…
Matched conditions: ERΑ+ BREAST CANCER
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New radiation drug shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …
Matched conditions: ERΑ+ BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental immunotherapy cocktail takes on tough tumors
Disease control OngoingThis early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…
Matched conditions: ERΑ+ BREAST CANCER
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC